Mobile

A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuva...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-014419-11

A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunological equivalence (in terms of vaccine-homologous virus H1N1 HI antibody GMTs) of the Quebec-manufactured A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03A and the Dresden-manufactured A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03A, 21 days after the first vaccination in healthy subjects aged 18 to 60 years. Criteria for equivalence: Immunological equivalence will be demonstrated if the limits of two-sided 95% confidence interval for the GMT ratio (Flu D-PAN H1N1 vaccine over Flu Q-PAN H1N1 vaccine) in terms of HI antibody titre against A/California/7/2009 (H1N1)v-like strain are within the 0.5 - 2.0 interval.

Critère d'inclusion

  • Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years

Liens